Why Major Drugmakers Are Overhauling How They Build Complex Medicines

2026-09-10 companies

New York, Thursday, 10 September 2026.
Global biopharmaceutical companies are fundamentally restructuring their supply chains, abandoning traditional vendor contracts in favor of long-term strategic partnerships with development and manufacturing organizations. As pipeline development tilts toward complex modalities—such as targeted therapies, peptides, and high-potency active ingredients, which now account for over 40% of new candidates in development—in-house technical demands have surged. To navigate strict regulatory hurdles and capital efficiency demands, drugmakers rely on specialized partners for advanced solutions, ranging from continuous manufacturing to high-containment automation. These integrated alliances are yielding critical results: strategic process optimizations have boosted production yields by over 90% and shortened drug filing timelines to eight months. Furthermore, major market moves, including multi-billion-dollar acquisitions in the peptide manufacturing sector, highlight an aggressive industry-wide shift toward securing reliable, specialized capacity. Strategic alignment and governance are becoming as essential as scientific innovation in bringing modern therapeutics to market.

Operationalizing Complex Modalities

The transition from transactional contracts to integrated partnerships is driven by the technical demands of modern drug modalities. WuXi AppTec, operating as a Contract Research, Development, and Manufacturing Organization (CRDMO), has reported utilizing enabling technologies such as flow chemistry and biocatalysis to simplify synthetic routes for complex small molecules and peptides [1][2]. In a specific case study involving a divalent-siRNA-GalNAc conjugate, the company implemented new solid-support and synthesis strategies that increased crude sense strand purity by over 85% and final yield by over 90% [1][2]. This optimization enabled the client to meet an Investigational New Drug (IND) filing deadline within 8 months, highlighting the critical impact of specialized technical infrastructure on development timelines [1][2]. Furthermore, the company’s Couvet, Switzerland facility completed a Phase 3 manufacturing process transition and scale-up in 5 months, allowing a client to submit a New Drug Application (NDA) on schedule [1][2]. These examples underscore the industry-wide shift where capital efficiency and regulatory navigation necessitate deep technical collaboration rather than simple vendor execution [1][2].

Governance and Regulatory Oversight

As partnerships deepen, governance frameworks must evolve to prevent operational friction and ensure compliance. Regulatory guidance from the FDA mandates that pharmaceutical companies maintain active oversight of outsourced activities through written quality agreements that delineate current good manufacturing practice (cGMP) responsibilities [3]. Despite this, a 2024 study of 294 medical-product-industry respondents revealed that only 44% defined crisis roles and responsibilities in initial regulatory agreements [3]. Effective governance requires clearly defined decision rights and escalation pathways to resolve technical and quality disputes before they cause broader program delays [3]. A 2025 industry survey of over 100 CDMO and pharmaceutical industry leaders revealed misaligned priorities, with CDMOs prioritizing speed and flexibility while pharma companies prioritized reliability and communication [3]. Additionally, more than 70% of established pharmaceutical respondents in the 2025 survey anticipated moderate-to-significant capacity constraints throughout 2025, emphasizing the need for robust partnership structures [3].

Capital Movements and Capacity Expansion

Major market participants are executing significant capital maneuvers to secure capacity in high-demand sectors. In mid-July 2026, Samsung Biologics offered to acquire Switzerland-based CDMO PolyPeptide for CHF 1.46 billion ($1.8 billion) to expand into peptide manufacturing, specifically targeting GLP-1 projects [6]. Subsequently, Samsung Biologics announced a rights offering on 31 August 2026 to raise KRW 3 trillion ($2.2 billion), with funds earmarked for the acquisition and expanding the Bio Campus II in Incheon [6]. Concurrently, Lonza announced an expanded strategic collaboration on 1 July 2026 with an unnamed U.S.-based biopharmaceutical company, adding two commercial biologics programs with an option for two more [6]. These movements correlate with growth in the High Potency Active Pharmaceutical Ingredients (HPAPI) market, which was valued at $29.9 billion in 2025 and is projected to reach $31.6 billion in 2026 [8]. The market growth calculation 1.7 indicates a $1.7 billion increase in one year, reflecting the surging demand for specialized containment and manufacturing capabilities [8].

Global Strategic Realignment

Global dynamics are shifting, with industry leaders noting changes in valuation and speed of development across regions. At the NLSDays 2026 conference in Stockholm, experts discussed the diminishing era of 便宜 Chinese licensing deals, noting that average upfront deal values roughly doubled in the first two months of 2026 compared to the same period in 2025 [7]. The Chinese pharmaceutical pipeline now includes 6,000 to 7,000 known active programs, and for the first time in 2025, more drugs had their first global launch in China than in the United States [7]. Meanwhile, Nordic and European biotech faces an innovation cliff due to weak pricing rewards and capital access barriers compared to the U.S. [7]. Looking forward, industry forecasts suggest that over the next five years, the HPAPI sector will see continued growth driven by oncology and antibody-drug conjugate payloads, with a shift toward greater automation and geographic diversification [8]. By 2031, the most competitive facilities are predicted to be defined by closed, flexible, and automated systems backed by robust scientific expertise [8].

Sources

CDMO partnerships pharma outsourcing